Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 6/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14352914 | 0.86 | ALDH2 (0.57) | ALDH2PPARAROCK2CYP3A4CYP2D6 | |
| SCHEMBL14352861 | 0.80 | ALDH2 (0.56) | ALDH2PPARACYP3A4CYP2C9 | |
| SCHEMBL14353010 | 0.77 | ALDH2 (1.00) | ALDH2HDAC1PTGESMAPT | |
| SCHEMBL14352883 | 0.77 | ALDH2 (0.66) | ALDH2ALDH1A1MAPT | |
| SCHEMBL14353276 | 0.76 | HDAC1 (0.50) | HDAC1MAPTHDAC6SLC13A5 | |
| SCHEMBL14477706 | 0.67 | SLC13A5 (0.41) | CYP3A4CYP2D6ALDH1A1MAPTSLC13A5 | |
| SCHEMBL2571157 | 0.67 | HDAC1 (0.55) | ALDH2HDAC1HDAC2 | |
| SCHEMBL18699124 | 0.66 | ALDH2 (0.50) | ALDH2ALDH1A1MAPT | |
| SCHEMBL14352988 | 0.66 | ALDH2 (0.46) | ALDH2ALDH1A1 | |
| SCHEMBL26922991 | 0.65 | ALDH2 (0.49) | ALDH2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-11-29 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2993170-B1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2993170-A1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | Gilead Sciences, Inc. (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2726460-B1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9000015-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2726460-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140051668-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8575353-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013006400-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
| US-20140051668-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885PPARA 2493/4885KDM1A 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.